IPP Bureau
Firstsource and Guidehealth partner to advance AI-enabled value-based care for health plans
By IPP Bureau - August 17, 2025
The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation
UFlex posts Q1 FY26 PAT at Rs. 58 Cr
By IPP Bureau - August 17, 2025
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr
By IPP Bureau - August 17, 2025
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
Zydus’ SEZ II, Ahmedabad plant clears USFDA inspection with nil observations
By IPP Bureau - August 16, 2025
The inspection concluded with NIL observations
Cohance Lifesciences reports 13% revenue growth in Q1 FY26
By IPP Bureau - August 16, 2025
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
AbbVie to invest $195 million to expand API manufacturing in North Chicago
By IPP Bureau - August 16, 2025
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
Brightmark and Lewis Salvage recycle over 1 million pounds of medical plastics
By IPP Bureau - August 16, 2025
Medical plastics make up about 25 per cent of the 14,000 tons of waste generated daily in US healthcare facilities
AAVantgarde Bio receives FDA fast track designation for AAVB-039 in stargardt disease
By IPP Bureau - August 16, 2025
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs
By IPP Bureau - August 16, 2025
Attorney General Ken Paxton sued pharmaceutical giant Eli Lilly for bribing and illegally inducing medical providers to prescribe its most profitable drugs
Eight Roads Ventures to host fourth edition of Scale-Up Health conference on Sept 10
By IPP Bureau - August 14, 2025
The conference will explore the path to India’s first billion-dollar drug, evolution towards value-based healthcare, biotech breakthroughs, and the role of AI and LLMs in care delivery
Indoco Remedies receives final USFDA approval for rivaroxaban tablets
By IPP Bureau - August 13, 2025
Rivaroxaban is used to treat venous thromboembolism
Senores Pharmaceuticals acquires ANDAs from Teva Pharmaceuticals USA
By IPP Bureau - August 13, 2025
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
Apollo Hospitals Q1 FY26 PAT up 42% to Rs. 433 Cr
By IPP Bureau - August 13, 2025
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
By IPP Bureau - August 13, 2025
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Granules India Q1 FY26 PAT slips to Rs. 112.6 Cr
By IPP Bureau - August 13, 2025
